Target intelligence / Profile preview

Cilium assembly protein DZIP1L (DZIP1L)

Target
DZIP1L
Molecular classification
Zinc finger protein (C2H2-type zinc finger motif), Ciliary transition zone/basal body protein, Other: coiled-coil domain protein
01

Overview

DZIP1L (Cilium assembly protein DZIP1L) is a zinc finger and coiled-coil domain containing protein that localizes to centrioles, basal bodies, and the ciliary transition zone, playing an essential role in the formation and architecture of primary cilia[1][2][4][5]. Mutations in DZIP1L are a genetic cause of autosomal recessive polycystic kidney disease (ARPKD), affecting the proper distribution and function of PKD proteins (polycystin-1 and polycystin-2) at the ciliary membrane. DZIP1L modulates the gating function of the transition zone/transition fibers, which controls entry of soluble and membrane proteins into cilia[1][2][5]. Deficiency leads to severe kidney phenotypes including polycystic changes, hypertension, and renal failure[1]. DZIP1L does not currently have established pharmacological modulators or known drug interactions, but its gene and protein serve as important clinical biomarkers for genetic diagnosis and mechanistic investigation of ARPKD and other ciliopathies[1][2][5].

Other names
DAZ interacting zinc finger protein 1 likeDZIP1LFLJ32844DZIP2DAZ-interacting zinc finger protein 1-likePKD5Cilium assembly protein DZIP1LDAZ interacting protein 1-likeDAZ-interacting protein 1-like proteinZinc finger protein DZIP1L
02

Mechanism of action

Not applicable (no drugs directly targeting DZIP1L have mechanism of action described in the literature).

03

Biological functions

Cilium assemblyRegulation of protein localization, including PKD1/PC1 and PKD2/PC2Modulation of ciliary transition fibers architecture and gatingCell compartmentalization (centrioles, basal bodies, transition fibers)
04

Disease associations

Autosomal recessive polycystic kidney disease (ARPKD) (causal gene)Other ciliopathies (as a ciliary gating protein)
05

Safety considerations

Loss-of-function mutations associated with early-onset ARPKD, enlarged polycystic kidneys, impaired cortico-medullary differentiation, arterial hypertension, and progression to end-stage renal diseaseNo data on drug safety/therapeutic targeting safety in humans.
06

Biomarkers

DZIP1L gene mutations for ARPKD patient selection/genetic diagnosisFunctional biomarkers: altered ciliary distribution of PC1 and PC2 in DZIP1L-mutant cells

Beyond the preview

Go deeper on Cilium assembly protein DZIP1L (DZIP1L).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cilium assembly protein DZIP1L (DZIP1L).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call